Deutsche Bank Starts Achillion Pharmaceuticals (ACHN) at Buy, Calls Under-Appreciated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
BofA/Merrill Lynch Upgrades Achillion Pharmaceuticals (ACHN) to Buy
September 19, 2012 6:28 AM EDTBofA/Merrill Lynch upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Underperform to Buy.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $8.10 yesterday, with a 52 week range of $3.81-$12.95.... More
